Therapeutic modalities that overcome the antiapoptotic function of Bcl-2 that is often overexpressed in cancer cells are expected to be a novel strategy for cancer treatment. We previously reported that the leukemic cell death induced by an N-terminally truncated Bax (DN Bax: corresponding to amino acid 112-192 of full-length Bax) was not blocked by Bcl-2 or Bcl-x L owing to the lack of the BH3 domain needed to interact with the antiapoptotic Bcl-2 family molecules. In this study, we used the Cre-loxP system that allowed us to propagate adenoviruses expressing DN Bax, and investigated the effects of the DN Bax gene transfer into A549 and NCI-H1299 nonsmall cell lung cancer cell lines. DN Bax showed more cell-death-inducing activity in both cells than did the full-length Bax in vitro. It was found that the DN Bax-induced cell death was not inhibited by the pancaspase inhibitor z-VAD-fmk, suggesting that DN Bax induces cell death through a caspase-independent mechanism. Intratumoral injection of adenoviruses expressing DN Bax into A549 tumors in Balb/c nude mice showed a significantly stronger suppression of tumor growth (74%) than full-length Bax (25%) compared to the control. Our results suggest that DN Bax may provide a better alternative than currently used cytotoxic genes in cancer gene therapy trials.
Introduction
Recent advances in the area of cancer chemotherapy have expanded its effectiveness for most cancers. However, one of the major obstacles of chemotherapy is that cancers often become resistant to chemotherapeutic agents (Beck and Dalton, 1997) . Such agents exert their anticancer effects by activating endogenous apoptosis pathways that lead to cell death (Huang, 2000; Herr and Debatin, 2001) , and it is considered that aberrations of these pathways are frequently responsible for the resistance (Costantini et al., 2000; Igney and Krammer, 2002) . Several mechanisms that impair the pathway function have been reported in cancers: (i) molecules such as p53, death receptors, and their related molecules that directly activate the apoptosis pathway are dysfunctional (Takahashi et al., 1989; Takimoto ElDeiry l, 2000) ; (ii) Bax, a key molecule in the pathway, is antagonized by the overexpression of Bcl-2 protein (Oltvai et al., 1993) ; and (iii) caspases that directly catalyze DNA fragmentation are suppressed by inhibitors of apoptosis (IAP) family molecules that are overexpressed (Ambrosini et al., 1997; Tamm et al., 1998) . Modalities that can repair these abnormalities and thus restore the normal pathway function will be useful for establishing novel cancer treatments.
Bax is one of the proapoptotic factors that belong to the Bcl-2 family, and its overexpression leads to apoptosis in a wide variety of mammalian cells (Oltvai et al., 1993) . Although the precise mechanism remains to be elucidated, mitochondria are considered to be a target of the Bax action (Green and Reed, 1998) . Bax, which normally resides in the cytoplasm, translocates into mitochondria in response to apoptotic stimuli . After translocation, it elicits the release of cytochrome c from mitochondria (Eekes et al., 1998; Finucane et al., 1999) and disrupts the electrical potential across the inner membrane (Pastorino et al., 1998) . Both are important biochemical events that lead to apoptosis (Green and Reed, 1998; Gross et al., 1999) . Bax protein has several functional domains ( Figure 1a ). BH3 is a regulatory domain of Bax. Through the BH3 domain, Bax forms homodimers to promote apoptosis or heterodimers with Bcl-2 and Bcl-x L to silence itself (Yin et al., 1994; Hunter and Parslow, 1996; Wang et al., 1998) .
Crystallographic studies of Bcl-2 family members have shown their striking resemblance to certain bacterial toxins (Muchmore et al., 1996; Aritomi et al., 1997; Suzuki et al., 2000) . The expression of Bax was lethal both in Escherichia coli and in yeast (Jurgensmeier et al., 1997) , and the C-terminal domain of Bax (DN Bax: corresponding to amino acids 112-192) was sufficient to induce cell death in E. coli (Ishibashi et al., 1998) . Overexpression of DN Bax in mammalian leukemic cell lines induced cell death that was unable to be suppressed by Bcl-2 or Bcl-x L (Ishibashi et al., 1998) . This may be attributed to the lack of the BH3 domain without which Bax cannot form heterodimers with Bcl-2 and Bcl-x L These results suggest that DN Bax may effectively induce cancer cell death by escaping the antiapoptotic activity of Bcl-2 and Bcl-x L , which are frequently overexpressed in human cancer cells (Pezzella et al., 1993; Ikegaki et al., 1994) .
We hypothesized that the overexpression of DN Bax in cancer cells could cause cell death more effectively than the full-length Bax. In this study, we investigated the effects of DN Bax in lung cancer cell lines both in vitro and in vivo using an adenovirus-mediated gene delivery system. We also present several lines of evidence indicating that DN Bax induces cancer cell death in a caspase-independent manner.
Results

Expression of DN Bax in nonsmall cell lung cancer cells
Adenoviruses are usually propagated in 293 cells. If the recombinant genes inserted into the virus are toxic to 293 cells, the yield of the virus will be low. Many genes with expected utility in cancer treatment are cytotoxic, and the above-described limitation compromises the use of adenoviruses. To overcome this problem, we used a Cre-loxP-based adenovirus system (Figure 1b) . This system allowed us to expand the viruses in 293 cells.
The virus titer of AdCALNDNBax and AdCALNBax expressed as plaque-forming units (PFU)/ml was over 1 Â 10 11 PFU/ml and almost equivalent to other E1-deleted adenovirus vectors.
A cotransfection of silent form adenoviral vectors (AdCALNDNBax or AdCALNBax) and an adenoviral vector encoding Cre recombinase (AdCANCre) successfully expressed DN Bax and full-length Bax in both A549 and NCI-H1299 cells (Figure 2 ). Although fulllength Bax was not distinguishable from endogenous Bax protein, the intensity of the band from the protein infected with full-length Bax was apparently higher than in negative controls. As expected, DN Bax was expressed as a 10 kDa protein that is smaller than Bax protein at 48 and 72 h after infection. Neither adenoviral delivery of DN Bax nor full-length Bax changed the basal expression levels of Bcl-2 and Bcl-x L (Figure 2 ). NCI-H1299 cells did not express detectable Bcl-2 protein.
Overexpression of DN Bax is more cytotoxic in both A549 and NCI-H1299 cells in vitro Adenoviral delivery of DN Bax induced cell death in both A549 and NCI-H1299 cells at a lower multiplicity of infection (moi) than did full-length Bax (Figure 3 ). The 50% cell-growth inhibition (IC 50 ) for DN Bax and full-length Bax were 3 and 10 moi in A549 cells and 6 and 20 moi in NCI-H1299 cells, respectively. Deletion of the N-terminal portion of Bax augmented the cell-deathinducing activity over three times (Po0.05) in these cancer cell lines.
Morphologic features of cell death induced by DN Bax
To elucidate the potent mechanisms of cancer cell death induced by DN Bax, we first visualized the nuclear (Figure 4a ). The cells infected with full-length Bax showed nuclear fragmentation and the presence of small apoptotic bodies, both of which are characteristic features of apoptotic cell death, by Hoechst 33258 staining. On the other hand, the cells infected with DN Bax showed condensed nuclear structures (Figure 4a ). When the cells presenting apoptotic cell death (fragmentation or apoptotic bodies) were counted, overexpression of DN Bax in A549 induced morphologically less apoptotic cell death (27%, Po0.01), compared to full-length Bax despite the high percentage of cell death by DN Bax (Figure 4b ). In addition, intense green fluorescence with MitoCapture TM was observed in A549 cells treated with DN Bax, indicating the loss of the mitochondrial potential (data not shown). These results suggest that DN Bax induces cell death in part by a different mechanism from that of the full-length Bax.
Mechanisms other than caspase-like protease activation are involved in DN Bax-induced cell death
In contrast to its significantly greater cell-death-inducing activity, DN Bax was a weaker caspase activator than full-length Bax (Figure 5a ). In NCI-H1299 cells, overexpression of full-length Bax was followed by activation of caspase-9 and caspase-3, but not by caspase-8, and finally followed by the induction of DNA laddering ( Figure 5c ). In contrast, DN Bax activated only caspase-3 and the magnitude of this activation was lower than that by full-length Bax, although DN Bax induced stronger DNA laddering than full-length Bax (Po0.01). Since caspase-9 activation is known to be an early event in the caspase-dependent cell death elicited by fulllength Bax (Li et al., 1997) , these results indicate that DN Bax evokes cell death, at least, in part in a caspaseindependent process. Consistent with these results, z-VAD-fmk, an inhibitor of caspase-like protease, failed to suppress DN Bax-induced cell-death, while it significantly suppressed the cell-death-inducing activity of full-length Bax (Figure 5b , c). Taken together, our results suggest that a caspase-independent pathway plays an important role in DN Bax-induced cell death. Similar results were also obtained in A549 cells (data not shown).
Effects of adenoviral delivery of DN Bax and full-length Bax in vivo
The effects of DN Bax and full-length Bax were studied in vivo by injecting adenoviruses three times into tumors established from A549 cells on days 4, 6, and 8. DN Bax significantly suppressed the tumor growth of A549 cells by 74% compared to the control vector expressing LacZ on day 40 (Po0.03, n ¼ 5), while full-length Bax suppressed the tumor growth by only 25% compared to the control vector (P>0.05, n ¼ 5) (Figure 6 ). Cell lysates isolated 24 h, 48 h, and 72 h after infection were electrophoresed on Tris-glycine gels and transferred to PVDF membranes. The specific bands were detected using anti-Bax, anti-Bcl-x L , and anti-Bcl-2 antibodies. The locations of the specific bands are marked on the right side. The endogenous and the exogenous full-length Bax proteins localize in the same position and thus cannot be distinguished. In NCI-H1299 cells, the expression of Bcl-2 protein could not be detected To investigate the mechanism of this strong tumor suppression, histological changes in the tumors were studied on day 7 after single intratumoral injection of adenoviruses. Both DN Bax and full-length Bax destroyed the tumor tissue structure (Figure 7a ). TUNEL-staining revealed over five times more TUNEL-positive cells in DN Bax-treated tumors than in full-length Bax-treated tumors (Figure 7a , b, Po0.001). Intratumoral adenoviral injections did not elevate the serum AST or ALT levels (measured on day 3 and day 7; data not shown) nor did it affect the body weights. Our results suggest that intratumoral adenoviral delivery of DN Bax may be a powerful and safe method for treating cancers.
Discussion
In this report, we have constructed an adenoviral vector encoding a truncated form of Bax or full-length Bax under the regulation of the Cre/loxP system. We hypothesized that artificially truncated Bax, DN Bax, could cause cancer cell death more effectively than fulllength Bax because DN Bax is not affected by the antiapoptotic factors Bcl-2 and Bcl-x L . Our results both in vitro and in vivo demonstrated a stronger induction of cancer cell death by DN Bax than by full-length Bax, supporting this hypothesis. DN Bax and full-length Bax presented discordant morphological changes, suggesting that different apoptotic mechanisms are involved. In the DN Bax-transduced cells, nuclear DNA showed the marked laddering characteristic of apoptotic cell death but the DNA laddering was not suppressed by the caspase inhibitor zVAD-fmk. This suggests that a caspase-independent mechanism may be involved in the DN Bax-induced cell death.
Direct targeting of cancer cells with gene therapy may make possible the treatment of cancer on the basis of its molecular characteristics. But, although laboratory results have been encouraging, only a few clinical trails could demonstrate direct tumor regression (McCormick, 2001) . In this context, proapoptotic factors have recently been studied for cancer gene therapy because these factors can directly and effectively induce apoptosis in the target cells (Fan et al., 1999; Tai et al., 1999; Yamashita et al., 2002) . Among these factors, Bax is the most well-known proapoptotic molecule of the Bcl-2 family (Gross et al., 1999) , and its ability to induce apoptosis is dependent on its ratio to that of the antiapoptotic Bcl-2 family members such as Bcl-2 or Bcl-x L (Oltvai et al., 1993) . DN Bax with retention of the pore-forming domain (amino acids 106-153) but deletion of the BH3 domain could result in a potent molecule capable of inducing cancer cell death by avoiding the suppression of antiapoptotic heterodimerization with Bcl-2 or Bcl-x L .
Since high levels of Bcl-2 expression are often found in human lung cancers (Pezzella et al., 1993; Ikegaki et al., 1994) , DN Bax can be expected to outperform the killing effect of full-length Bax (Figure 3 After 48 h, the cells were incubated with 5 mg/ml PI to stain dead cells and 25 mg/ml Hoechst 33258 to stain nuclear chromatin. (b) Quantification of cell death judged by nuclear morphology. Cells stained with PI were counted as dead cells. Cells that stained positive with PI and exhibited nuclear fragmentation by Hoechst 33258 staining were scored as cell death with nuclear fragmentation. To quantify morphological changes, an average of 200 nuclei from random fields were analysed. The ratios of the dead cells (dead cells/ total nuclei) and the dead and nuclear-fragmented cells (dead and fragmented nuclei/total nuclei) were ploted. Three random fields were examined in each group. Significant differences (Po0.01) are marked by asterisks (*) DN Bax is a strong cell-death inducer K Usui et al
Bax induces the caspase-dependent programmed cell death by releasing cytochrome c from the mitochondrial intermembrane space. The released cytochrome c binds to Apaf-1 and triggers the oligomerization of Apaf-1, which in turn recruits procaspase-9 to the apoptosome complex (Li et al., 1997) . Recruitment of procaspase-9 into the apoptosome causes its autoactivation of downstream caspases such as caspase-3 (Li et al., 1997; Eekes et al., 1998) . We have shown that the overexpression of full-length Bax induces apoptosis with its characteristic nuclear fragmentation and apoptotic bodies, and that there were activated caspase-9 and -3 indicating a mitochondria-mediated apoptosis pathway. This apoptotic pathway was blocked by a pan-caspase inhibitor, z-VAD-fmk. In contrast, despite the fact that DN Bax induced stronger cell death and DNA laddering, DN Bax-treated cells showed different morphological changes of the nuclei and weaker activation of capsase-9 and -3. Furthermore, z-VAD-fmk failed to block the cell death induced by DN Bax. These results suggested that DN Bax does not induce cell death through a caspasedependent mechanism.
In recent years, a caspase-independent pathway induced by some stimuli appeared (Xiang et al., 1996; Sperandio et al., 2000; Li et al., 2001) . None of the caspase-independent apoptosis was inhibited by z-VADfmk. Although TUNEL-positive cell death and DNA laddering that relate to internucleosomal cleavage are characteristics for typical apoptosis, caspase-independent apoptosis has been recently reported to induce similar TUNEL-positive cell death and DNA laddering in the late phase of cell death in cancer cells and neurons (Cregan et al., 2002; Wu et al., 2002) . In a search for molecules responsible for caspase-independent apoptosis, the apoptosis-inducing factor (AIF) was identified (Susin et al., 1999) . AIF normally locates in the After 48 h, caspase-like protease activities of 100 mg of cell lysate protein were measured using colorimetric substrates DVED-pnitroaniline (pNA) (for caspase-3-like activity), IETD-pNA (for caspase-8-like activity), or LEHD-pNA (for caspase-9-like activity). pNA released from each substrate upon cleavage was monitored by a spectrophotometer at 405 nm (n ¼ 3). Fold increases compared with the mock-infected groups are shown. Values represent the means7s.d. Significant differences compared with mock-infected groups are marked by asterisks (*). Caspase-3 activation by DN Bax was significantly weaker than that by full-length Bax (marked by #: Po0.01). (b) Inhibition of caspase-like protease activity. NCI-H1299 cells were infected with AdCALNDNBax, AdCALNBax, or AdCALNLZ (20 moi) plus AdCANCre (6 moi) with or without z-VAD-fmk (50 mm). After 72 h cell viability was evaluated (n ¼ 3). z-VAD-fmk did not inhibit DN Bax-induced cell death (#), while it significantly inhibited full-length Bax-induced cell death (*, Po0.001). (c) DNA ladder formation. NCI-H1299 cells were infected with AdCALNDNBax, AdCALNBax, or AdCALNLZ (20 moi) and AdCANCre (6 moi) with or without z-VAD-fmk (50 mm). After 72 h, DNA was extracted and electrophoresed in 1% agarose gel and stained with ethidium bromide. The photograph shows a representative result from three independent experiments. z-VAD-fmk did not inhibit DNA ladder formation by DN Bax while it inhibited that of full-length Bax transmembrane space of mitochondria, translocates to the nucleus upon death signals, and causes chromosome condensation and large-scale DNA fragmentation. These effects are independent of caspase activities. Joseph et al. reported an AIF-mediated caspaseindependent cell death by staurosporine in nonsmall cell lung cancer, although caspases were activated by staurosporine (Joseph et al., 2002) . In this context, AIF might be involved in the cell-death pathway induced by DN Bax.
Furthermore, members of antiapoptotic factors such as IAP family that are often overexpressed in human cancer cells interrupt cell death by caspase-dependent pathways (Tamm et al., 1998) . Therefore, it can be suggested that one reason for the stronger induction of cancer cell death by DN Bax may be the activation of a caspase-independent pathway without the counter balance of such inhibitors.
Gene transfer of Bax through adenoviral vectors has been shown to induce apoptosis in several types of cancer cells in vivo as well as in vitro. To avoid the toxicity of the transgene in the packaging cells, two different techniques, a dual-vector system and an inducible promoter, have been employed. Human telomerase reverse transcriptase promoter enables the specific expression of the Bax gene in cancer cells (Gu et al., 2000 (Gu et al., , 2002 . Kagawa et al. employed a dual adenoviral vector system, Ad/GT-Bax and Ad/ PGK-GV-16, to express Bax in lung cancer A549 and H1299 cells (Kagawa et al., 2000a, b) . Although this report demonstrated strong suppression of tumor growth in vivo, we could not show a similar suppressive effect by full-length Bax. This discrepancy may be attributed to the different expression system and different treatment protocols.
With regard to a possible clinical application, safety issues should first be addressed. Overexpression of Bax causes apoptosis of normal cells. Therefore, it is likely that DN Bax would also cause death of normal cells. In a previous report, infusion of a dual adenoviral vector expressing Bax gene to the tail vein of mice caused apoptosis in liver cells (Kagawa et al., 2000b) . Although intratumoral injection of DN Bax did not cause overt adverse effects in mice, it is possible that extravasation of DN Bax-expressing virus could cause apoptosis of normal tissue cells. A tumor-specific promoter should therefore be employed to target DN Bax specifically to the nonsmall cell lung cancer even when the Cre-loxP system is being used in clinical trials.
In conclusion, the Cre/loxP adenoviral system expressing DN Bax strongly suppressed the tumor growth of human lung cancer. Gene therapy with DN Bax may provide a better alternative to the cytotoxic genes currently used in cancer gene therapy.
Materials and methods
Construction of adenoviruses
The recombinant adenoviral vectors were generated using the adenovirus Cre-loxP system (Kanegae et al., 1995) (Takara Biomedical, Shiga, Japan), which enables propagation of adenoviruses with toxic genes such as Bax or DN Bax (Figure 1b) . This system utilizes two plasmids: (i) pAxCALNLw that contains the CAG-promoter, a stuffer fragment between two loxP sites, a cloning site for SwaI, and the rabbit b-globin polyadenylation signal in this order, and (ii) pAxCANCreDNA-TPC that contains a Cre recombinase expression cassette. When cells are simultaneously infected with the two adenoviruses produced from each plasmid, the stuffer is excised in the target cells and the inserted gene is expressed (Figure 1b) . Bax cDNA or the DN Bax cDNA (Ishibashi et al., 1998) was inserted into the SwaI site of pAxCALNLw. A control plasmid, pAxCALNLZDNA-TPC, which contains the E. coli b-galactosidase gene, was obtained from Takara Biomedical. Four adenoviruses, AdCANCre, AdCALNLZ, AdCALNBax, and AdCALNDNBax, were generated from these plasmids using the COS-TPC method (Kanegae et al., 1995) . All viruses were propagated in 293 cells, purified twice by ultra centrifugation in a cesium chloride gradient, and dialyzed against phosphate-buffered saline (PBS). The titer for each virus vector was determined by the plaque assay and expressed as PFU/ml. All viral preparations were confirmed negative for E1 plus adenovirus contamination by PCR.
Western blot analysis
Cells were lysed in lysis buffer containing RIPA buffer and protease inhibitors (Roche Molecular Biochemicals, Indianapolis, IN, USA). A total of 20 mg of soluble protein per sample were separated in 10-20% polyacrylamide Tris-glycine gradient gels and transferred to polyvinylidene fluoride (PVDF) filters. The filters were blocked in Tris-buffered saline containing 10% skimmed milk. They were then incubated overnight at 41C with one of the following primary antibodies: rabbit antihuman Bax polyclonal antibody (N-20, Santa Cruz Biotechnology, Inc, CA, USA), rabbit anti-human Bax polyclonal antibody (Ab-1, Oncogene product, Cambridge, MA, USA), mouse anti-human Bcl-2 monoclonal antibody (C-2, Santa Cruz Biotechnology, Inc., CA, USA), or rabbit anti-human Bcl-x L antibody (S-18, Santa Cruz Biotechnology, Inc., CA, USA). Filters were then incubated with donkey anti-rabbit immunoglobulin horseradish peroxidase conjugates (Amersham Pharmacia Biotech, Dubendorf, Switzerland) at RT for 1 h. Visualization of the immunocomplex was performed by chemiluminescence using the ECL kit (Amersham Pharmacia Biotech), followed by exposure to Polaroid film.
Cell lines and cell survival assay
Human nonsmall cell lung cancer cells A549 and NCI-H1299 were obtained from the American Type Culture Collection, and cultured in RPMI-1640 medium and in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and antibiotics, respectively. The cells plated into 96-well plates (1 Â 10 3 per well) were infected with AdCALNBax, AdCALNDNBax, or AdCALNLZ at an moi of 2-125 in the presence of AdCANCre at an moi of one-third. Cell viability was determined 96 h after infection by AlamarBlue (BIOSOURCE, Camarillo, CA, USA) according to the manufacturer's protocol. The experiments were performed more than three times for each cell line.
Morphological analysis of the nuclear structure A549 cells (1 Â 10 4 cells per well) cultured overnight in an eight well Lab-Tek II Chamber Slide (Nalge Nunc International, Naperville, IL, USA) were infected with a mixture of 10 moi of AdCALNDNBax, AdCALNBax, or AdCALNLZ, and 3 moi of AdCANCre. After 48 h, the cells were quickly rinsed with PBS, stained with 5 mg/ml of propidium iodide (PI) (Sigma, St Louis, MO, USA) for 1 min, and again rinsed with PBS. Then, these cells were fixed with ice-cold methanol for 5 min and stained with 25 mg/ml of Hoechst 33258 (Sigma, St Louis, MO, USA). The cells were observed by fluorescence microscopy at Â 400 magnification. Cells that stained positive for PI were counted as dead cells. Cells that stained positive for PI and exhibited the nuclear fragmentation by Hoechst 33258 were scored as nuclear-fragmented dead cells. An average of 200 nuclei from three random fields was analysed.
DNA ladder formation
A549 cells (5 Â 10 5 cells per six-well dish) were infected with a mixture of 20 moi of AdCALNDNBax, AdCALNBax, or AdCALNLZ, and 6 moi of AdCANCre. After 48 h, DNA was extracted with DNA extraction buffer (10 mm Tris HCl, pH 7.4. 10 mm EDTA, 0.5% Triton X-100). The extracted DNA was electrophoresed on a 1% agarose gel, stained with ethidium bromide, and photographed.
Caspase-3, -8, and -9 activities Caspase-3-like protease activity in cell lysates was analysed using the CaspACE assay system kit (Promega, Madison, WI, USA). Caspase-8-like and caspase-9-like protease activities in cell lysates were analysed using the MBL kit (Medical Biological Laboratories, Nagoya, Japan). Briefly, cells were lysed in a lysis buffer from the supplier and centrifuged at 14 000 r.p.m at 41C for 20 min. The soluble cytoplasmic protein (100 mg) thus obtained was mixed with 200 mm of DEVD-pnitroaniline (pNA) (caspase-3 specific substrate) (ProMega, Madison, CA, USA), LEHD-pNA (caspase-9 specific substrate) (Medical Biological Laboratories, Nagoya, Japan), or IETD-pNA (caspase-8 specific substrate) (Medical Biological Laboratories) in a final volume of 100 ml and incubated at 371C. The substrate cleavage was monitored by the absorbance at 405 nm using a SPECTRAmax 340 microplate reader (Molecular Devices, Sunnyvale. CA, USA). The contribution of the caspase activity to the apoptotic process by full-length Bax and DNBax was studied by a pan-caspase inhibitor, z-VAD-fmk (50 mm) (Medical Biological Laboratories). Cell viability was assessed using AlamarBlue 96 h after infection.
In vivo study
All animal experiments were carried out in accordance with the guidelines of the Institute of Development, Aging, and Cancer, Tohoku University. A549 cells (5 Â 10 6 ) were subcutaneously injected into the dorsal flank of athymic Balb/c nu/nu mice (8 weeks) on Day 0. Tumors were measured two to three times per week. Tumor volumes were calculated using the formula a Â b 2 Â 0.5 (mm 3 ), where a is the large diameter and b is the small diameter. The tumor volumes were approximately 50 mm 3 on day 4. The mice were given three doses of intratumoral injections of 100 ml of 1Â 10 9 PFU of AdCALNLZ, AdCALNBax, or AdCALNDNBax mixed with one-third moi of AdCANCre on days 4, 6, and 8. For histological analysis, 7 days after infection, the mice were killed and the tumors were excised, fixed with 10% formalin, and embedded in paraffin. Tissue sections were subjected either to hematoxylin-eosin staining or to TUNEL staining using the In situ Apoptosis Detection kit (Takara Biomedical, Shiga, Japan). More than three random fields were examined and the apoptotic cells were counted at Â 200 magnification.
